Purpuric rash of meningococcemia.
London
Vanessa
V
Internal Medicine, California Pacific Medical Center, San Francisco, California, USA.
Aronowitz
Paul
P
D000890:Anti-Infective Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000188:drug therapy / Q000382:microbiology*; D002443:Ceftriaxone / Q000627:therapeutic use; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D008297:Male; D008589:Meningococcal Infections / Q000188:drug therapy / Q000382:microbiology*; D008875:Middle Aged; D009345:Neisseria meningitidis / Q000302:isolation & purification*; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D010878:Piperacillin / Q000627:therapeutic use; D000077725:Piperacillin, Tazobactam Drug Combination; D011486:Protein C / Q000627:therapeutic use; D011693:Purpura / Q000382:microbiology*; D011994:Recombinant Proteins / Q000627:therapeutic use; D014640:Vancomycin / Q000627:therapeutic use
D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents; D011486:Protein C; D011994:Recombinant Proteins; D000077725:Piperacillin, Tazobactam Drug Combination; D014640:Vancomycin; D002443:Ceftriaxone; D010397:Penicillanic Acid; C421124:drotrecogin alfa activated; D006854:Hydrocortisone; D010878:Piperacillin